Lilly's oral GLP-1, Foundayo (orforglipron), demonstrated cardiovascular safety alongside sustained A1C reduction and weight loss in its largest and longest type 2 diabetes study
PR Newswire•30/09/2026•18:00 ET
5
Key Highlights
- ➤Foundayo (LLY) cut MACE-4 risk 16% versus insulin glargine
- ➤Foundayo (LLY) cut MACE-3 risk 23% versus insulin glargine
- ➤Foundayo (LLY) showed 53% lower cardiovascular death risk versus insulin glargine
- ➤Foundayo (LLY) showed 57% lower all-cause death risk versus insulin glargine
- ➤Foundayo (LLY) delivered sustained A1C reduction and weight loss in ACHIEVE-4
Expert Statements
Klara Klein, Assistant Professor of Medicine, University of North Carolina School of Medicine
“For people living with type 2 diabetes, protecting the heart is as important as controlling blood sugar.”
Klara Klein, Assistant Professor of Medicine, University of North Carolina School of Medicine
“ACHIEVE-4 reaffirmed the safety of orforglipron and demonstrated an association with a lower risk of major cardiovascular events and death.”
Klara Klein, Assistant Professor of Medicine, University of North Carolina School of Medicine
“These results, paired with the simple administration of a once-daily pill, taken without fasting or water restrictions, could make orforglipron a compelling potential option across the globe.”
Lilly's oral GLP-1, Foundayo (orforglipron), demonstrated cardiovascular safety alongside sustained A1C reduction and weight loss in its largest and longest type 2 diabetes study PR Newswire
In ACHIEVE-4, participants taking Foundayo experienced a 16% lower risk of MACE-4 and a 23% lower risk of MACE-3, meeting the primary objective for non-inferiority compared to insulin glargine
Get started
Create a free account to read the full story.